What is Sarepta Therapeutics Inc Annual Revenue?

Sarepta Therapeutics Inc Annual Revenue rose 52.97%, in the last year to $1,901.98 M. Its sector's average revenue growth for the last fiscal year was 7.49%.

What is Sarepta Therapeutics Inc Annual Net Profit?

Sarepta Therapeutics Inc Annual Net Profit rose 143.89% in the last year to $235.24 M. Its sector's average net profit growth for the last fiscal year was -32.44%.

What is Sarepta Therapeutics Inc Price to Earning Ratio?

Sarepta Therapeutics Inc Price to Earning Ratio is 22.78, higher than its sector PE ratio of 3.14.

What is Sarepta Therapeutics Inc Stock Price?

Sarepta Therapeutics Inc Stock Price fell 52.23% and underperformed its sector by 59.04% in the past year.

What is Sarepta Therapeutics Inc Quarterly Revenue?

Sarepta Therapeutics Inc Quarterly Revenue rose 65.94% YoY to $658.41 M. Its sector's average revenue growth YoY for the quarter was 5.79%.

What is Sarepta Therapeutics Inc Quarterly Net profit?

Sarepta Therapeutics Inc Quarterly Net profit rose 248.37% YoY to $159.05 M. Its sector's average net profit growth YoY for the quarter was -41.98%.

What is Sarepta Therapeutics Inc Debt to Equity Ratio?

Sarepta Therapeutics Inc Debt to Equity Ratio of 0.88 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Sarepta Therapeutics Inc Return on Equity(ROE)?

Sarepta Therapeutics Inc Return on Equity(ROE) for the last financial year was 19.71%, in the normal range of 10% to 20%.

What is Sarepta Therapeutics Inc Mutual Fund Holding?

Sarepta Therapeutics Inc Mutual Fund Holding decreased by 1.83% in the last quarter to 80.86.

What is Sarepta Therapeutics Inc Promoter Share Holding?

Sarepta Therapeutics Inc Promoter Share Holding increased by 0.14% in the most recent quarter to 6.26%.

What is Sarepta Therapeutics Inc Interest Coverage Ratio?

Sarepta Therapeutics Inc Interest Coverage Ratio is 15.18, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).

What is Sarepta Therapeutics Inc Institutional Holding?

Sarepta Therapeutics Inc Institutional Holding increased by 0.63% in the last quarter to 93.78.

How is the Sarepta Therapeutics Inc today?

The Sarepta Therapeutics Inc today is trading in the green, up by 2.68% at 55.23.

How has Sarepta Therapeutics Inc performed historically?

The Sarepta Therapeutics Inc is currently trading up 2.68% on an intraday basis in the past week the index rose 8.23%. The index has been down -53.19% in the past quarter and fell -52.23% in the past year. You can view this in the overview section.

Sarepta Therapeutics Inc XNAS: SRPT

Sarepta Therapeutics Inc Live Share Price Today, Share Analysis and Chart

Name: Sarepta Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Sarepta Therapeutics Inc
Rating: 2.704861125
Author: Trendlyne DVM scores

Falling Comet

Download real time

55.23 1.44 (2.68%)

68.12% Fall from 52W High

1.5M XNAS Volume

XNAS 21 Apr, 2025 5:30 PM (EDT)

Board Meeting

The next board meeting for Sarepta Therapeutics Inc is on 01 May 2025 for the purpose of Sarepta Therapeutics Inc First Quarter Earnings Conference Call for 2025 See details

Sarepta Therapeutics Inc Key Metrics

My Metrics

Default

Market Capitalization High in industry Unavailable in chosen country	5,359.1
PE TTM High in industry Unavailable in chosen country	22.8
PEG TTM Below industry Median Unavailable in chosen country	0.2
Price to Book Below industry Median Unavailable in chosen country	3.5
Institutional holding current Qtr % High in industry Unavailable in chosen country	93.8
Revenue Growth Qtr YoY % Below industry Median Unavailable in chosen country	65.9
Operating Revenue growth TTM % Below industry Median Unavailable in chosen country	53
Net Profit Qtr Growth YoY % High in industry Unavailable in chosen country	248.4
Net Profit TTM Growth % High in industry Unavailable in chosen country	143.9
Operating Profit Margin Qtr % High in industry Unavailable in chosen country	24.6
Operating Profit Margin TTM % Below industry Median Unavailable in chosen country	11.5
Piotroski Score High in industry Unavailable in chosen country	6
Rel Perf vs Sector quarter% Unavailable in chosen country	-52.6
ROE Annual % High in industry Unavailable in chosen country	19.7
RoA Annual % High in industry Unavailable in chosen country	6.5

All financials are in USD Million and price data in USD

High Financial Strength

77.8 / 100

Mid Valuation

34.8 / 100

Technically Bearish

26.0 / 100

Falling Comet These stocks are the ones with good quality and mid-range financial aspects. However, their weak technical aspect reduces the investor's interest. View Similar Embed DVM

154

1Yr Price target upside is 179%

24 analysts

Check Before You Buy

Check P/E Buy Sell Zone

Strong Buy Zone

3.0 % into P/E buy sell zone

Strong upside potential

% time spent below current P/E

Gains already realized

Sarepta Therapeutics Inc Stock Price Analysis

Day Price Range 2.7% 1 Day return Unavailable in chosen country	55.2 (LTP) 52.856.1 LowHigh
Week Price Range 8.2% 1 Week return Unavailable in chosen country	55.2 (LTP) 51.456.3 LowHigh
Month Price Range -24.8% 1 Month return Unavailable in chosen country	55.2 (LTP) 4876.7 LowHigh
52 Week Price Range -52.2% 1 Year return Unavailable in chosen country	55.2 (LTP) 48173.2 LowHigh

View full Share Price History

Sarepta Therapeutics Inc Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Hit

Sarepta Therapeutics Inc's Revenue was higher than average estimate 3 times in past 3 years

EPS forecast

QUARTER
ANNUAL

Current EPS

2.3

Avg. Estimate

6.8

Low Estimate

0.6

High Estimate

14.5

Current EPS

Avg. Estimate

Hit

EPS is expected to grow by 189.7% in FY25

Consensus Recommendation

25 ANALYST Recommendations

BUY

The consensus recommendation from 25 analysts for Sarepta Therapeutics Inc is BUY

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Sarepta Therapeutics Inc Stock Analysis

Sarepta Therapeutics Inc stock analysis with key metrics, changes, and trends.

Sarepta Therapeutics Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Revenue	$1,901.98 M	52.97%	positive	Annual Revenue rose 52.97%, in the last year to $1,901.98 M. Its sector's average revenue growth for the last fiscal year was 7.49%.
Annual Net Profit	$235.24 M	143.89%	positive	Annual Net Profit rose 143.89% in the last year to $235.24 M. Its sector's average net profit growth for the last fiscal year was -32.44%.
Price to Earning Ratio	22.78	-	negative	Price to Earning Ratio is 22.78, higher than its sector PE ratio of 3.14.
Stock Price	$55.23	-52.23%	negative	Stock Price fell 52.23% and underperformed its sector by 59.04% in the past year.
Quarterly Revenue	$658.41 M	65.94%	positive	Quarterly Revenue rose 65.94% YoY to $658.41 M. Its sector's average revenue growth YoY for the quarter was 5.79%.
Quarterly Net profit	$159.05 M	248.37%	positive	Quarterly Net profit rose 248.37% YoY to $159.05 M. Its sector's average net profit growth YoY for the quarter was -41.98%.
Debt to Equity Ratio	0.88	-	positive	Debt to Equity Ratio of 0.88 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	19.71 %	19.71%	neutral	Return on Equity(ROE) for the last financial year was 19.71%, in the normal range of 10% to 20%.
Mutual Fund Holding	80.86 %	-1.83%	negative	Mutual Fund Holding decreased by 1.83% in the last quarter to 80.86.
Promoter Share Holding	6.26 %	0.14%	positive	Promoter Share Holding increased by 0.14% in the most recent quarter to 6.26%.
Interest Coverage Ratio	15.18	-	positive	Interest Coverage Ratio is 15.18, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).
Institutional Holding	93.78 %	0.63%	positive	Institutional Holding increased by 0.63% in the last quarter to 93.78.

VIEW LESS

Loading data..

Sarepta Therapeutics Inc - Company Profile

What does Sarepta Therapeutics Inc do?

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

Gross Remuneration

2024

Gross Remuneration

Year

Sarepta Therapeutics Inc Live Share Price Today, Share Analysis and Chart

68.12% Fall from 52W High

Sarepta Therapeutics Inc Key Metrics

Market Capitalization

PE TTM

PEG TTM

Rel Perf vs Sector quarter%

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

ROE Annual %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

RoA Annual %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Sarepta Therapeutics Inc Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Sarepta Therapeutics Inc Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Sarepta Therapeutics Inc's Revenue was higher than average estimate 3 times in past 3 years

EPS forecast

EPS is expected to grow by 189.7% in FY25

Consensus Recommendation

The consensus recommendation from 25 analysts for Sarepta Therapeutics Inc is BUY

Sarepta Therapeutics Inc Stock Analysis

Sarepta Therapeutics Inc stock analysis with key metrics, changes, and trends.

Annual Revenue rose 52.97%, in the last year to $1,901.98 M. Its sector's average revenue growth for the last fiscal year was 7.49%.

Annual Net Profit rose 143.89% in the last year to $235.24 M. Its sector's average net profit growth for the last fiscal year was -32.44%.

Price to Earning Ratio is 22.78, higher than its sector PE ratio of 3.14.

Stock Price fell 52.23% and underperformed its sector by 59.04% in the past year.

Quarterly Revenue rose 65.94% YoY to $658.41 M. Its sector's average revenue growth YoY for the quarter was 5.79%.

Quarterly Net profit rose 248.37% YoY to $159.05 M. Its sector's average net profit growth YoY for the quarter was -41.98%.

Debt to Equity Ratio of 0.88 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was 19.71%, in the normal range of 10% to 20%.

Mutual Fund Holding decreased by 1.83% in the last quarter to 80.86.

Promoter Share Holding increased by 0.14% in the most recent quarter to 6.26%.

Interest Coverage Ratio is 15.18, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).

Institutional Holding increased by 0.63% in the last quarter to 93.78.

Sarepta Therapeutics Inc - Company Profile

What does Sarepta Therapeutics Inc do?

Sarepta Therapeutics Inc Management structure

Mr. Ryan Edward Brown

Executive Vice President, Chief General Counsel and Corporate Secretary

Mr. Cristin Rothfuss

Executive Vice President and General Counsel

Mr. Douglas S. Ingram,Esq.

Director, President and Chief Executive Officer

Mr. Ian Michael Estepan

Executive Vice President, Chief Financial Officer and Principal Accounting Officer

Sarepta Therapeutics Inc Board of directors

Ms. Deirdre P. Connelly

Director

Mr. Douglas S. Ingram,Esq.

Director, President and Chief Executive Officer

Dr. M. Kathleen Behrens Wilsey, PhD